An Australian biotech company is already turning heads so far on Wednesday after it was announced results from its GBM-AGILE, which is a phase II/III study that included an...

To read the full story on AllPennyStocks.com, click here.

Grafico Azioni Kazia Therapeutics (NASDAQ:KZIA)
Storico
Da Feb 2025 a Mar 2025 Clicca qui per i Grafici di Kazia Therapeutics
Grafico Azioni Kazia Therapeutics (NASDAQ:KZIA)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di Kazia Therapeutics